Respiratory News and Research

RSS

China Pharma third quarter revenue increases 12% to $21.0 million

China Pharma Holdings, Inc., a specialty pharmaceuticals company in China, today announced financial results for the quarter ended September 30, 2011.

11 Nov 2011

NYU Langone professor offers guidance on risk factors, interventions for SUDEP

Over time, epileptic seizures can lead to major health issues, including significant cognitive decline and even death, warns Orrin Devinsky, MD, professor, Departments of Neurology, Neurosurgery and Psychiatry at NYU Langone Medical Center.

11 Nov 2011

Wood stoves with chimneys linked to reduced childhood pneumonia

Cooking stoves with chimneys can lower exposure to indoor wood smoke and reduce the rate of severe pneumonia by 30 percent in children less than 18 months of age, according to a new air pollution study funded by the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health.

11 Nov 2011

Long-range wind transport of an infectious agent may cause KD

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. In fact, if not diagnosed or treated in time, it can lead to irreversible heart damage. After 50 years of research, including genetic studies, scientists have been unable to pinpoint the cause of the disease.

10 Nov 2011

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

GenMark Diagnostics, Inc. today reported financial results for the third quarter ended September 30, 2011.

10 Nov 2011

PlusNews examines difficulties in diagnosing, treating MDR-TB in children

PlusNews examines the difficulties in diagnosing and treating multidrug resistant tuberculosis (MDR-TB) in children, writing, "With weaker immune systems, children who contract TB -- most often from parents -- progress to active disease in about a year. But just how many children are affected is not known as there is almost no research into children and MDR-TB -- and very little useful guidance on how to treat them."

10 Nov 2011

Mylan acquires rights to Pfizer's inhalation technology platform

Mylan Inc. today announced that it has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair Diskus and Seretide Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform.

10 Nov 2011

U.N., aid groups appeal for additional funding, supplies for Pakistan flood victims

The U.N. and several other international aid groups, including Oxfam, Save the Children, Care and ACTED, on Wednesday "warn[ed] they are running short of money and supplies to help millions of people affected by floods in Pakistan," the Associated Press reports.

10 Nov 2011

POPG inhibits influenza infections in cell cultures and mouse models

A natural lipid in the fluid lining the lungs inhibits influenza infections in both cell cultures and mouse models, according to researchers at National Jewish Health. These findings, combined with previous studies demonstrating effectiveness against respiratory syncytial virus, suggest that the molecule, known as POPG, may have broad antiviral activity.

10 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Sleep paralysis more frequent among students and psychiatric patients

What do Moby Dick, the Salem witch trials and alien abductions all have in common? They all circle back to sleep paralysis.

9 Nov 2011

Celgene to initiate apremilast Phase III placebo-controlled trial for ankylosing spondylitis

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced data from a Phase II study of apremilast, its investigational oral immunomodulatory compound, in patients with ankylosing spondylitis (AS) were presented at the American College of Rheumatology Scientific Meeting in Chicago, IL.

9 Nov 2011

QRxPharma receives FDA written acceptance for review of MoxDuo IR NDA

QRxPharma Limited announced today it received written acceptance from the United States Food and Drug Administration (FDA) for review of the MoxDuo IR New Drug Application (NDA) filed earlier this year.

9 Nov 2011

First Edition: November 8, 2011

Today's early morning highlights from the major news organizations, including stories on malpractice reforms and previews of voting in Ohio on two ballot questions affecting health care issues and a Mississippi abortion issue.

8 Nov 2011

QRxPharma receives date for US pain drug launch, pending approval

Australian pain-relief drug developer QRxPharma (QRX) has announced today that they have received from the US Food & Drug Adminstration.

8 Nov 2011

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

8 Nov 2011

MRSA co-infection increases risk of flu-related mortality among children

During the 2009 H1N1 influenza pandemic, many previously healthy children became critically ill, developing severe pneumonia and respiratory failure, sometimes fatal. The largest nationwide investigation to date of influenza in critically ill children, led by Children's Hospital Boston, found one key risk factor: Simultaneous infection with methicillin-resistant Staphylococcus aureus (MRSA) increased the risk for flu-related mortality 8-fold among previously healthy children.

7 Nov 2011

Respiratory problems in homes on the rise due to air freshners

Sales of home air fresheners and scented candles are on the rise and so are respiratory problems in homes where these products are used, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Nov 3-8.

7 Nov 2011

New study questions effectiveness of current exercise referral schemes

Research commissioned by the NIHR Health Technology Assessment programme and carried out by research teams from the Peninsula College of Medicine and Dentistry (PCMD) and the Universities of Exeter (Sport and Health Sciences) and Brunel (Health Economics Research Group), has called into question the effectiveness of exercise referral schemes as they are delivered at present.

7 Nov 2011

Teleflex to showcase respiratory solutions, education programs at AARC Congress

Teleflex Incorporated will showcase a number of respiratory solutions and education programs at the annual American Association of Respiratory Care Congress to be held in Tampa, Florida on November 5-8, 2011.

5 Nov 2011